Apitegromab
Sources
registry, as of 2026-01-23Stale
https://clinicaltrials.gov/study/NCT06445075
Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese. Overall status COMPLETED. Phases PHASE2. Lead sponsor Scholar Rock, Inc.. Enrollment 102. Conditions Overweight and Obesity. A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
ClinicalTrials.gov NCT06445075 protocol and results modules
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT06445075
during the treatment period. Apitegromab Apitegromab (SRK-015) is a fully human anti-proMyostatin monoclonal antibody (mAb) that specifically binds to human pro/latent myostatin, inhibiting myostatin activation. Apitegromab was administered every 4 weeks by intravenous (IV) infusion. Placebo Same
NCT06445075 description or intervention text